According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020, or nearly one in six deaths. Here are 3 small…

next round of trials on its target therapy PTX-100 for blood cancers. The company completed the first round of its Phase 1b trials of the…

Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment in the expansion cohort of the Phase 1b trial of…

Prescient Therapeutics Ltd (ASX:PTX)’s Steven Yatomi-Clarke explains how the company is combatting the leading, global cause of death with its novel, personalised therapy pipeline. Prescient…

Prescient Therapeutics (PTX) has opened patient enrolments for an expanded phase 1B trial of its PTX-100 therapy to treat T-cell lymphomas, a group of aggressive…

Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it builds out an expanded clinical study in 2022. Leading ASX…

Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in treating aggressive rare blood cancers where the company says there…

Cancer results from the mutation of normal cells to tumour cells because of interaction between a person’s genetic factors and carcinogens. As per the Australian…

Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in the first half of the financial year, its reports show….

ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards its clinical and development milestones. The results announced by the…